BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$0.58 USD
+0.03 (6.31%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $0.58 0.00 (-0.82%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for BioXcel Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 65 | 194 | 233 | 213 | 32 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2 | 2 | 0 | 0 | 0 |
Other Current Assets | 5 | 7 | 4 | 4 | 2 |
Total Current Assets | 72 | 203 | 237 | 217 | 34 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 1 | 0 | 0 | 0 |
Total Assets | 74 | 206 | 239 | 220 | 36 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 14 | 10 | 5 | 4 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 22 | 11 | 7 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 1 | 0 | 0 |
Total Current Liabilities | 27 | 33 | 17 | 12 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 101 | 93 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 2 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 130 | 129 | 18 | 13 | 10 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 534 | 488 | 467 | 346 | 84 |
Retained Earnings | -591 | -412 | -246 | -139 | -57 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -57 | 77 | 222 | 207 | 27 |
Total Liabilities & Shareholder's Equity | 74 | 206 | 239 | 220 | 36 |
Total Common Equity | -57 | 77 | 222 | 207 | 27 |
Shares Outstanding | 29.90 | 28.00 | 27.90 | 24.30 | 18.00 |
Book Value Per Share | -1.89 | 2.74 | 7.95 | 8.51 | 1.49 |
Fiscal Year End for BioXcel Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 56 | 74 | 65 | 90 | 128 |
Receivables | 1 | 0 | 0 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 2 | 2 | 2 | 2 |
Other Current Assets | 4 | 4 | 5 | 6 | 8 |
Total Current Assets | 64 | 81 | 72 | 99 | 138 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 65 | 82 | 74 | 100 | 140 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 13 | 17 | 14 | 11 | 11 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 14 | 14 | 13 | 27 | 22 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 2 | 1 |
Total Current Liabilities | 27 | 31 | 27 | 39 | 35 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 103 | 102 | 101 | 99 | 97 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 9 | 2 | 2 | 2 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 140 | 155 | 130 | 141 | 134 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 551 | 545 | 534 | 528 | 524 |
Retained Earnings | -626 | -617 | -591 | -568 | -518 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -74 | -72 | -57 | -41 | 6 |
Total Liabilities & Shareholder's Equity | 65 | 82 | 74 | 100 | 140 |
Total Common Equity | -74 | -72 | -57 | -41 | 6 |
Shares Outstanding | 40.70 | 37.00 | 29.90 | 29.20 | 29.10 |
Book Value Per Share | -1.83 | -1.96 | -1.89 | -1.39 | 0.20 |